Posted on

Wellbeing Digital Sciences Reveals Recent Achievement By Its KGK Science Subsidiary

Wellbeing Digital Sciences Reveals Recent Achievement By Its KGK Science Subsidiary

The Company’s Wholly Owned Contract Research Organization is Currently  Working on Numerous Psychedelic Drug Projects, Clinical Trials, Path-to Market Consultations and New Substance Notifications, as the Continuation of a  Pivotal 2021 for KGK Science 

Vancouver, British Columbia, February 2, 2022 / Globe Newswire / – Wellbeing Digital  Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt:  MY0), an evidence-based healthcare company focused on innovative clinical solutions, artificial  intelligence-powered digital therapeutics and contract research, is pleased to provide a corporate  update highlighting the various achievements of its wholly owned subsidiary, KGK Science Inc.,  (“KGK” or the “CRO”).  

Recapping some of 2021’s highlights, KGK won contracts for 11 clinical trial service projects and  5 medical writing projects. Despite the restrictions associated with the COVID-19 pandemic,  KGK was able to complete the conduct of 9 clinical trials and advanced several others towards  completion. KGK’s Regulatory Division completed 19 consulting projects for clients in the  nutraceutical, cannabis and psychedelic spheres. KGK received approvals for eight Product  License Applications for Natural Health Products, acknowledgement letters for four unique New  Dietary Ingredient Notifications and expert panel consensus that three food ingredients possess  Generally Recognized As Safe status. Representatives of KGK were asked to be featured speakers  at the large Wonderland, Psychedelic Capital and Lift & Co. events, while the CRO was also a  major sponsor of the Miami-based Wonderland conference.  

For 2022, the CRO expects to experience significant growth based on current client interest in new  projects and requests for proposals, including a substantial expansion in psychedelics-related work.  KGK is currently working on psychedelic drug projects with eight distinct clients, managing four  clinical trials including a Phase 1 study of a proprietary psilocybin extract in healthy adults, and  working with an Ontario-based contract manufacturer to provide a joint solution for the production  and study of psychedelic compounds. Additionally, the CRO is working on 15 Product License  Applications submissions for Health Canada; seven pharmaceutical and 20 nutraceutical clinical 

trials, including two cannabis studies; as well as three paths-to-market and one new substance  notification.  

Internally, the CRO is helping Wellbeing enhance its network of clinics to conduct psychedelic  clinical trials. The Company’s goal is for KGK to become the premier contract research  organization in the psychedelics industry. An additional goal of Wellbeing is to improve virtual  trial conduct, by implementing a novel platform and technology along with its other subsidiary,  IRP Health, that the Company expects to be launched next year. As a result of their 2021  achievements, KGK advanced its reputation as an expert in the psychedelics sector and became a  founding member of the Psychedelic Science 2023 Event that is being planned as the world’s  largest gathering of people in the psychedelic ecosystem.  

“By the lengthy list of engagements currently under way, it is clear that KGK’s services are in  high demand. Our management team and employees are working hard every day to help clients  navigate the clinical trial process and regulatory environment. I’m incredibly proud of KGK’s  evolution and am grateful for the support of both our longstanding clients, new customers and  future collaborators,” said Najla Guthrie, President and CEO of KGK.  

“2021 was an important development year for both KGK and our overall organization as the  subsidiary was integrated after being acquired and synergies were quickly realized. With the large  number of clinical trials, research projects and collaborations with aligned counterparties already  under way at the CRO, management expects that 2022 may be even more rewarding. The  acquisition of KGK was definitely a highlight of last year and we look forward to growing together,  along with the rest of the organization,” added Adam Deffett, Interim CEO of Wellbeing.  

ABOUT KGK SCIENCE 

Founded in 1997, KGK is a leading North American contract research organization based in  London, Ontario that primarily provides high-quality clinical research trials with a focus on the  nutraceutical, cannabis and emerging psychedelic industries. The business has successfully helped  hundreds of companies with custom designed clinical trials and claim substantiation strategies to  move products into global markets. KGK’s other existing service lines include expert regulatory  support and compliance solutions, participant recruitment, research support services and  consulting services. On an approximate basis, the business to date has produced 150 publications,  executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in  its database and collected 10 million data points.  

ABOUT WELLBEING 

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based  healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital  therapeutics and contract research. Its mission is supported by a network of North American clinics  that provide ketamine-assisted therapies and other types of treatment to patients as well as through  a contract research organization that offer clinical trials services to clients pursuing drug 

development. In essence, the company exists to make breakthrough treatments more accessible  and to offer patients transformational experiences.  

On behalf of:  

WELLBEING DIGITAL SCIENCES INC. 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  

Email: ir@wellbeingdigital.co 

Web: www.wellbeingdigital.co 

Twitter: @Wellbeing_IR  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.  

Posted on

Nova Mentis and KGK Science Form Tactical Partnership

Nova Mentis and KGK Science Form Tactical Partnership

The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health Canada

Vancouver, British Columbia – January 27, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the Company has formed a tactical partnership with KGK Science Inc. (“KGK”), which is a wholly owned subsidiary of Wellbeing Digital Sciences Inc. (NEO: MEDI), to develop its psychedelic psilocybin drug portfolio in Canada. KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries. Both Companies plan to jointly submit a clinical trial application (“CTA”) to Health Canada for a Phase 2A clinical study evaluating psilocybin microdose therapy for fragile X syndrome.

“NOVA and KGK have synergistic capabilities that will facilitate submission of the CTA to Health Canada and achieve, in my opinion, no objection to this unprecedented clinical study,” stated Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board. “In our discussions with KGK, we realized early on that our two teams had the ability to navigate the entire lifecycle journey of our novel psilocybin microdose treatment of fragile X syndrome from a Phase 2A clinical study to drug approval and commercialization.”

“I am delighted to work with NOVA’s team to advance this novel initiative. NOVA’s microdose approach aims to address an unmet need that promises to have a significant impact on the lives of families impacted by fragile X syndrome. KGK is proud to be able to contribute and is confident our expertise will guide NOVA to success through the orphan drug pathway,” said Najla Guthrie, President and CEO of KGK.

NOVA’s research and clinical team initially identified unique opportunities in psychedelic drug development and chose a classic drug development pathway involving careful planning and execution of chemistry, manufacturing and preclinical proof of efficacy studies. The Company’s successes to date include but are not limited to:

  • NOVA is the first biotech company to achieve psilocybin orphan drug designation in both the United States and European Union;
  • Manufactured a large supply of >98% pure psilocybin for clinical studies and commercialization after drug approval;
  • Proof of efficacy and safety in preclinical rat models of autism spectrum disorder (ASD) and fragile X syndrome (FXS); 4 studies completed;
  • Established psilocybin microdose levels to treat FXS; and
  • Preparing Phase 2 chemistry and manufacturing file for regulatory submission.

KGK’s expertise includes:

  • Regulatory submission expertise;
  • Manage Investigational New Drug (“IND”) enabling activities;
  • Clinical trial design and trial execution;
  • Established clinical sites; and
  • In-house virtual behavioural testing models.

About KGK Science

Founded in 1997, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries. The business has successfully helped hundreds of companies with custom-designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. On an approximate basis, the business to date has produced 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points.

About Wellbeing Digital Sciences

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients as well as through a contract research organization that offer clinical trials services to clients pursuing drug development. In essence, the company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve psilocybin orphan drug designation in both the United States and European Union.

The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

For further information on the Company, please visit www.novamentis.ca or email info@novamentis.ca.

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc

Instagram: @novamentislsc

Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Posted on

Wellbeing Digital Sciences’ Subsidiary KGK Science Forms Tactical Partnership with Nova Mentis

Wellbeing Digital Sciences’ Subsidiary KGK Science Forms Tactical Partnership with Nova Mentis

The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application  to Health Canada  

Vancouver, British Columbia, January 27, 2022 / Globe Newswire / – KetamineOne Capital  Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt:  MY0), an evidence-based healthcare company focused on innovative clinical solutions, artificial  intelligence-powered digital therapeutics and contract research, is pleased to announce that its  wholly owned subsidiary, KGK Science Inc., (“KGK”), has formed a tactical partnership with  Nova Mentis Life Science Corp. (“Nova”) (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) to  help develop Nova’s psychedelic psilocybin drug portfolio in Canada. Nova is a biotechnology  company and global leader in first-in-class psilocybin-based therapeutics and complementary  diagnostics for neuroinflammatory disorders. Both Companies plan to jointly submit a clinical trial  application (“CTA”) to Health Canada for a Phase 2A clinical study evaluating psilocybin  microdose therapy for fragile X syndrome.  

“I am delighted to work with Nova’s team to advance this novel initiative. Nova’s microdose  approach aims to address an unmet need that promises to have a significant impact on the lives of  families impacted by Fragile X Syndrome. KGK is proud to be able to contribute and is confident  our expertise will guide Nova to success through the Orphan drug pathway,” said Najla Guthrie,  President and CEO of KGK.  

“Nova and KGK have synergistic capabilities that will facilitate submission of the CTA to Health  Canada and achieve, in my opinion, no objection to this unprecedented clinical study,” stated  Marvin S. Hausman MD, Nova SAB Chairman. “In our discussions with KGK, we realized early  on that our two teams had the ability to navigate the entire lifecycle journey of our novel psilocybin  microdose treatment of Fragile X Syndrome from a Phase 2A clinical study to drug approval and  commercialization.”  

Nova’s research and clinical team initially identified unique opportunities in psychedelic drug  development and chose a classic drug development pathway involving careful planning and  execution of chemistry, manufacturing and preclinical proof of efficacy studies. The Company’s  successes to date include but are not limited to: 

 Nova is the first biotech company to achieve psilocybin orphan drug designation in both  the United States and European Union;  

 Manufactured a large supply of >98% pure psilocybin for clinical studies and  commercialization after drug approval;  

 Proof of efficacy and safety in preclinical rat models of Autism Spectrum Disorder and  FXS with 4 studies completed;  

 Established psilocybin microdose levels to treat FXS; and  

 Preparing Phase 2 chemistry and manufacturing file for regulatory submission.  

KGK’s expertise includes:  

 Regulatory submission expertise;  

 Manage Investigational New Drug enabling activities;  

 Clinical trial design and trial execution;  

 Established clinical sites; and  

 In-house virtual behavioral testing models.  

ABOUT NOVA MENTIS LIFE SCIENCE CORP.  

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in  developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova  is the first biotech company to achieve psilocybin orphan drug designation in both the United  States and European Union. The goal is to diagnose and treat debilitating chronic conditions that  have unmet medical needs, such as Autism Spectrum Disorder (ASD) and Fragile X Syndrome  (FXS). For further information on the Company, please visit www.novamentis.ca or email  info@novamentis.ca.  

ABOUT KGK SCIENCE  

Founded in 1997, KGK is a leading North American contract research organization based in  London, Ontario that primarily provides high-quality clinical research trials with a focus on the  nutraceutical, cannabis and emerging psychedelic industries. The business has successfully helped  hundreds of companies with custom-designed clinical trials and claim substantiation strategies to  move products into global markets. KGK’s other existing service lines include expert regulatory  support and compliance solutions, participant recruitment, research support services and  consulting services. On an approximate basis, the business to date has produced 150 publications,  executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in  its database and collected 10 million data points.  

ABOUT WELLBEING DIGITAL SCIENCES  

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based  healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital  therapeutics and contract research. Its mission is supported by a network of North American clinics  that provide ketamine-assisted therapies and other types of treatment to patients as well as through  a contract research organization that offer clinical trials services to clients pursuing drug 

development. In essence, the company exists to make breakthrough treatments more accessible  and to offer patients transformational experiences.  

On behalf of:  

WELLBEING DIGITAL SCIENCES INC. 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  

Email: ir@wellbeingdigital.co 

Web: www.wellbeingdigital.co 

Twitter: @Wellbeing_IR  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.  

Posted on

Ketamine One Changes Name To Wellbeing Digital Sciences

Ketamine One Changes Name To Wellbeing Digital Sciences

The Company’s Common Shares Will Continue to Trade Under the Stock Symbol “MEDI” on the NEO Exchange, “KONEF” on the OTCQB Venture Market and “MY0” on the Frankfurt Stock Exchange

Vancouver, British Columbia, January 24, 2022 / Globe Newswire / – KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce that effective January 24, 2022 the Company will change its name to Wellbeing Digital Sciences Inc. (“Wellbeing”) from KetamineOne Capital Limited (collectively, the “Name Change”). Wellbeing will continue to trade under the stock symbol “MEDI” on the NEO Exchange (“NEO”), under the stock symbol “KONEF” on the OTCQB Venture Market and under the symbol “MY0” on the Frankfurt Stock Exchange. 

“We are excited to announce our new name and reveal our updated branding that is better aligned with our multidisciplinary approach, which encompasses mental and physical health through the pursuit of a variety of traditional and novel digital therapeutics. Wellbeing Digital Sciences is a name that acknowledges each one of our three core pillars: clinic-based treatments, contract research and health technology,” said Adam Deffett, Interim CEO of WellBeing. “Our mission continues to be the implementation of an innovative and bespoke healthcare offering to underserved populations, such as military veterans and first responders. The stage is set for this year to be a pivotal one for the Company, as many of our technology partnerships, clinical trials and network growth initiatives are expected to come to fruition,” added Mr. Deffett.

The Company also reaffirms that its pursuits continue to be centred around the following mission and vision statements:

  • To bring a technology-first approach to psychedelic therapies and drug development;
  • To operate a network of clinics that support treatments, future research, clinical trials and the integration of digital therapeutics; and
  • To advance the integration wearable technology and artificial intelligence-powered technology partnerships into each patient’s experience.

In accordance with the Name Change, the Company has launched a new website at www.wellbeingdigital.co. The new website prominently features the strength and clarity of the new Wellbeing brand, with content that includes more information about the Company, the market potential, mental health, a patient portal, investor materials and news. Further, the contact information for investors and other interested parties contained on the website as well as within this news release has been updated to reflect the Name Change. Employee email addresses have also been updated, while Wellbeing’s new social media profiles have been secured and will be launched in due course.

ABOUT WELLBEING

Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients as well as through a contract research organization that offer clinical trials services to clients pursuing drug development. In essence, the company exists to make breakthrough treatments more accessible and to offer patients transformational experiences.

On behalf of:

WELLBEING DIGITAL SCIENCES INC.

“Adam Deffett“

Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations

Tel: 1-844-746-6351

Email: ir@wellbeingdigital.co 

Web: www.wellbeingdigital.co

Twitter: @Wellbeing_IR

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Posted on

Ketamine One Becomes Exclusive Ketamine Treatment Provider To Victoria Wellness

Ketamine One Becomes Exclusive Ketamine Treatment Provider To Victoria Wellness

Utilizing its Previously Announced Partnership with iHealthOX, the Company Will Provide Initial Assessments and Consultations of, Develop Care Plans for and Administer IV or Oral Ketamine Therapy to Victoria Wellness’ Appropriate Clients in Ontario

Vancouver, British Columbia, January 17, 2022 / Globe Newswire / – KetamineOne Capital Limited  (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company  focused on consolidating medical clinics and becoming a North American leader in mental health  treatments, is pleased to announce that the Company has entered into a one-year agreement with Victoria  Wellness Mental Health Residential and Addition Treatment Centre (“VW” or the “Centre”) for Ketamine  One to be the Centre’s exclusive ketamine treatment provider. Located at 5316 Rice Lake Scenic Drive in  Gores Landing, Ontario, VW is a residential rehabilitation facility and mental clinic focused on treating  anxiety, depression and post-traumatic stress disorder (“PTSD”) by offering personalized therapy treatment  programs with a connection to nature to both veterans and the general public.  

The Company and the Centre have launched a first class, best practice-based, six-week inpatient Ketamine  Integrated Therapy Experience (“KITE”) program. The first three weeks of the KITE program is being  structured to offer clients a unique opportunity to benefit from fast acting, evidence based and medically  supervised ketamine administration in order to help combat long standing and prescription resistant mental  health conditions such as depression and PTSD. Doses of ketamine will be supplemented with specialized  and integrated ketamine-assisted psychotherapy (“KAP”). The KITE program will also see VW’s clients  embark on a comprehensive, premium, six-week residential recovery experience featuring the best in both  data-driven recovery therapies and holistic healing traditions.  

VW is looking to become a leader in the mental heath industry by incorporating KAP into its service  offering. The Centre already has veterans interested in the KITE program and treatments are expected to  begin shortly. Based on Ketamine One’s previously announced partnership, clients will be triaged and  psychologically assessed by iHealthOX. Those deemed appropriate for treatment will receive ketamine  intravenously at an off-site, third-party pain centre.  

“This exclusive agreement with VW is a meaningful opportunity to help even more veterans and other  members of the general public who are battling daily with anxiety, depression and PTSD. Ketamine One  looks forward to working with the VW team over the next year and beyond,” said Steven Inglefield, Chief 

Operating Officer of Ketamine One. “Growing our network of clinics, both directly and indirectly such as  through this agreement, is a core part of the Company’s competitive strategy. We are working hard to  expand our operations and, ultimately, what that means is working hard to help more people,” added Mr.  Inglefield.  

“Thank you to Ketamine One for your persistent in the mental health field to allow all Canadians the  opportunity to end their mental health struggles with the benefits of ketamine. I am thrilled to form a  partnership with Ketamine One to become a leader in the mental health field in Canada. This partnership  allows us to provide inpatient residential care with ketamine to the veterans, military and first responders  who are suffering from PTSD, depression and other mental health issues. From my own personal  experience, you can get better and our KITE program is designed to help you fly,” said Joe Ann Kortman,  Executive Director of VW.  

Additionally, Ketamine One is please to report that data collection from the first participants in the  previously announced single arm, open label study of patients with PTSD who are undergoing the  proprietary physical therapy program at the Company’s IRP Health clinics began on January 4, 2022. And  lastly, the Company is pleased to announce that the re-branding of IRP Health is now complete. Interested  parties can visit www.irphealth.ca to experience the new brand.  

ABOUT KETAMINE ONE 

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating  medical clinics and becoming a North American leader in mental health treatments. It is working to provide  the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently,  Ketamine One has a network of clinics across North America, with plans to further consolidate the highly  fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which  places it at the forefront of premium clinical research based on the subsidiary’s history and extensive  experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective  enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental  health therapy.  

On behalf of:  

KETAMINE ONE 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-PHONE-K1 (1-844-746-6351)  

Email: IR@ketamine.one  

Web: www.ketamine.one 

Twitter: @KetamineOne  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers 

are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.   

INTERESTED IN WORKING WITH KETAMINE ONE?

If you’re interested in being a financial partner, clinic partner, or community advocate, we’d love to talk. partners@ketamine.one

Posted on

Ketamine One Begins Trading On The OTCQB Marketplace On January 12, 2022

Ketamine One Begins Trading On The OTCQB Marketplace On January 12, 2022

The Up-Listing of the Company’s Common Shares to the OTCQB Coincides with its Recent Receipt of DTC Eligibility, which Enhances the Ability of US Investors to Become  Shareholders of Ketamine One  

Vancouver, British Columbia, January 12, 2022 / Globe Newswire / – KetamineOne Capital Limited  (“Ketamine One” or the “Company”) (NEO: MEDI) (OTCQB: KONEF) (Frankfurt: MY0), a  company focused on consolidating medical clinics and becoming a North American leader in mental health  treatments, is pleased to announce that its common shares have been successfully up-listed (the “Up 

Listing”) from the OTC Pink Sheet Open Market to the OTCQB Venture Market (the “OTCQB”) by the  OTC Markets Group Inc. (“OTC Markets”). The Company’s common shares will begin trading on the  OTCQB under the symbol “KONEF” as of the opening of the market on January 12, 2022. The Up-Listing  complements the Company’s previous receipt of DTC Eligibility. Ketamine One’s common shares will  continue to trade on the NEO Exchange under the symbol “MEDI” and the Frankfurt Stock Exchange under  the symbol “MY0”.  

Operated by OTC Markets, the OTCQB offers transparent trading in entrepreneurial and development stage  companies that have met a minimum bid price test, are current in their financial reporting and have  undergone an annual verification and management certification process. The OTCQB is recognized by the  United States (“US”) Securities and Exchange Commission as an established public market providing  public information for analysis and value of securities. These standards provide a strong baseline of  transparency, as well as the technology and regulations to improve the trading experience for investors.  

Ketamine One has a verified profile and is 12g3-2(b) Certified by OTC Markets. Investors or other  interested parties in the US can obtain real-time quotes for Ketamine One as well as access its most current  news and other information at www.otcmarkets.com. Shareholders will also now have greater access to  information via the OTC Disclosure and News Service, as well as transparent prices through full depth-of 

book with Real Time Level 2 quotes.  

“We are pleased for Ketamine One’s common shares to be accepted onto the OTCQB by OTC Markets.  The listing of our shares on the OTCQB is important as it makes it easier for American investors to obtain  information about our securities and purchase our stock. Combined with DTC Eligibility, the Up-Listing  enables US residents who are interested in the mental health revolution to become shareholders and  participate in our growth,” said Adam Deffett, Interim Chief Executive Officer of Ketamine One. “Now  with our common shares being listed on the NEO Exchange, Frankfurt Stock Exchange and OTCQB, it is 

easier than ever before for investors in the world’s major capital markets to become owners of Ketamine  One’s securities,” added Mr. Deffett.  

ABOUT KETAMINE ONE 

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating  medical clinics and becoming a North American leader in mental health treatments. It is working to provide  the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently,  Ketamine One has a network of clinics across North America, with plans to further consolidate the highly  fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which  places it at the forefront of premium clinical research based on the subsidiary’s history and extensive  experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective  enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental  health therapy.  

On behalf of:  

KETAMINE ONE 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-PHONE-K1 (1-844-746-6351)  

Email: IR@ketamine.one  

Web: www.ketamine.one 

Twitter: @KetamineOne  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above. 

SOURCE: KetamineOne Capital Limited

INTERESTED IN WORKING WITH KETAMINE ONE?

If you’re interested in being a financial partner, clinic partner, or community advocate, we’d love to talk. partners@ketamine.one

Posted on

Ketamine One Subsidiary KGK Science Becomes the First Founding Sponsor of the “Psychedelic Science 2023” Event

Ketamine One Subsidiary KGK Science Becomes the First Founding Sponsor of the “Psychedelic Science 2023” Event

Psychedelic Science 2023, Taking Place in Denver, Colorado from June 19-25, is Being Planned as the World’s Largest Gathering of the Psychedelic Ecosystem, Will Be Hosted by the Multidisciplinary Association for Psychedelic Studies and is Being Organized by Momentum Events

VANCOUVER, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization, KGK Science Inc. (“KGK” or the “CRO”), has become the first founding sponsor of the Psychedelic Science 2023 event (“Psychedelic Science 2023”). Taking place June 19-25, 2023 in Denver, Colorado with an estimated 10,000 attendees, Psychedelic Science 2023 will be the world’s largest gathering of the psychedelic ecosystem. The event will be hosted by Multidisciplinary Association for Psychedelic Studies (“MAPS”) and is being organized by Momentum Events.

Psychedelic Science 2023 will feature three days of panels, workshops, and lectures from leaders and visionaries from psychedelic research, education, policy, business, culture, and communities. Conference tracks will be complemented by pre- and post-conference workshops; an exhibit hall; and a marketplace featuring artists, musicians, and other vendors from around the world. Attendees will include MAPS members, donors, researchers, students, clinicians, advocates, therapists, political leaders, entrepreneurs, executives, investors, psychedelic enthusiasts, and those who may benefit from MAPS’ decades of research and advocacy.

Additionally, Ketamine One has granted 200,000 stock options (the “Options”) to a director of the Company, 1,901,402 restricted share units (the “RSUs”) to arm’s length advisors, and 150,000 common share purchase warrants (the “Performance Warrants”) to consultants to the Company. Each Option is exercisable to purchase one common share of the Company at a price of $0.27 per common share for a period of five years from the date of grant, in accordance with the Company’s stock option plan. The RSUs were issued pursuant to the Company’s restricted share unit plan approved by shareholders on Feb. 21, 2021. Fifty per cent of the RSUs vest six months from the date of grant, with the remaining fifty per cent of the RSUs vesting 12 months after the date of the grant. Each Performance Warrant was issued pursuant to the achievement of certain milestones set out in their respective engagement agreements, with 100,000 Performance Warrants being exercisable to purchase one common share of the Company at $0.50 per common share, and 50,000 Performance Warrants being exercisable to purchase one common share of the Company at $0.27 per common share. All Performance Warrants vest immediately upon issuance and have a two-year term.

ABOUT MOMENTUM EVENTS

Founded in 2012, Momentum Events proudly serves its clients and produces events that attract the best and brightest minds who come together to share their knowledge, connect with the individuals that matter most and enjoy valuable experiences online or in real life. Whether we’re developing cutting edge conferences for the markets served, or producing a partner’s next event, Momentum leverages its best-in-class technology platforms, an assortment of virtual and live event third-party provider relationships, and the meticulous nature of its event planning mindset to deliver true, sustainable value for all stakeholders. www.momentumevents.com.

ABOUT MAPS

Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since its founding, MAPS has raised over $130 million for psychedelic and marijuana research and education and has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator.

ABOUT KGK SCIENCE

Founded in 1997, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries. The business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. On an approximate basis, the business to date has produced 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

“Adam Deffett“
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Posted on

Ketamine One Appoints Two New Members to Its Medical Advisory Board

Ketamine One Appoints Two New Members to Its Medical Advisory Board

Corey Hilmas, MD, PhD and Brigadier General (Ret.) Loree K. Sutton, MD Will Help Guide the Development of the Company’s Mental Health Platform 

Vancouver, British Columbia, January 5, 2022 / Globe Newswire / – KetamineOne Capital Limited  (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company  focused on consolidating medical clinics and becoming a North American leader in mental health  treatments, is pleased to announce that Corey Hilmas, MD, PhD has been appointed to the Company’s  Medical Advisory Board (“MAB”) and will be assuming the role of Interim Chair of the MAB.  Additionally, Brigadier General (Ret.) Loree K. Sutton, MD, has also been appointed to the MAB.  

Dr. Hilmas currently also serves as the Chief Regulatory Officer of the Company’s wholly owned  subsidiary, KGK Science Inc. He is a respected scientist, medical doctor, and former federal food regulator  in the United States (“US”). After having completed his medical degree and doctorate in toxicology,  working as a principal investigator for many years, and serving on behalf of the US government at the Food  and Drug Administration (“FDA”), Dr. Hilmas combines his unique medical and scientific skillset with  extensive U.S. regulatory training. He served as an New Dietary Ingredients notification reviewer and as a  branch chief within the Division of Dietary Supplement Programs at the FDA.  

In addition to working on enforcement matters related to supplement labeling, claims, good manufacturing  practices and fraud, he also served as an expert witness for the FDA and Department of Justice, resulting  in an FDA Award of Merit from former FDA Commissioner Margaret Hamburg. As a recognized  regulatory expert with intimate knowledge of the dietary supplement industry, Dr. Hilmas has made  significant contributions to building and shaping the regulatory landscape through drafting over 65  comments to multiple US federal and state agencies as well as global food health directorates on topics  ranging from soy to supplements and cannabidiol, to changing regulatory frameworks overseas.  

Dr. Sutton is a lifelong public servant, physician and retired brigadier general who was the Army’s highest ranking psychiatrist. She is the co-founder of Threshold GlobalWorks, LLC; the founding commissioner of  the NYC Department of Veterans’ Services; and, in her current position as CEO, Veteran Services USA,  has devoted over 35 years of service and leadership to the nation and New York. Sutton’s decorated military  career includes earning a Bronze Star for her actions in combat while deployed to Operation Desert Storm.  Selected as a White House Fellow, the nation’s premier leadership program, and honored by the National  War College as a distinguished graduate, she also commanded the Carl R. Darnall Army Medical Center at  Fort Hood, TX during the height of Operation Iraqi Freedom hostilities. 

Serving as the founding director, Defense Centers of Excellence for Psychological Health and Traumatic  Brain Injury, Loree pioneered integrative approaches for building resilience, enhancing recovery and  fostering community reintegration. Spanning decades of service in the public and private sectors, her  visionary leadership has yielded transformational change which continues to improve the lives of veterans,  families, caregivers and survivors.  

Additionally, Ketamine One has granted certain advisors an aggregate amount of 100,000 stock options to purchase up to 100,000 common shares of the Company, at a price of $0.30 per common share for a period of five years from the date of grant, pursuant to its stock option plan that was approved by shareholders on Feb. 21, 2021. Fifty per cent of the options vest six months from the date of grant, with the remaining fifty per cent of the options vesting 12 months after the date of the grant.  

ABOUT KETAMINE ONE 

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating  medical clinics and becoming a North American leader in mental health treatments. It is working to provide  the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently,  Ketamine One has a network of clinics across North America, with plans to further consolidate the highly  fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which  places it at the forefront of premium clinical research based on the subsidiary’s history and extensive  experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective  enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental  health therapy.  

On behalf of:  

KETAMINE ONE 

“Adam Deffett”  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-PHONE-K1 (1-844-746-6351)  

Email: IR@ketamine.one  

Web: www.ketamine.one 

Twitter: @KetamineOne  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward 

looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by 

such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.  

Posted on

Ketamine One Reports Strong 1Q22 Financial Results

Ketamine One Reports Strong 1Q22 Financial Results

Revenues Reached Just Under $2.0 Million for the Quarter Ended October 31, 2021

VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has filed its financial results for the quarter ended October 31, 2021, which is the first quarter of the Company’s 2022 fiscal year ending July 31, 2022, the highlights of which are included in this news release. The full set of Consolidated Financial Statements and Management Discussion and Analysis can be viewed by visiting the Company’s website at www.ketamine.one or its profile page on SEDAR at www.sedar.com.

Financial Highlights (all amounts expressed in Canadian Dollars unless otherwise noted)

  • Revenue for the quarter ended October 31, 2021 reached $1,989,752, as compared to $nil for the same period of the prior year, which was primarily due to transitioning from an investment issuer to a single-purpose company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, while the Company’s wholly owned contract research organization, KGK Science Inc., also secured a significant amount of new business in the form of four contracts with third party clinical research and regulatory service clients;
  • Gross profit for the quarter ended October 31, 2021 was $594,411, as compared to $nil for the same period of the prior year, due to the aforementioned reasons;
  • Net loss for the quarter ended October 31, 2021 was $9,225,769, as compared to net loss of $605,810 reported for the same period of the prior year, primarily due to share based payments of $6,156,242, service fees of $941,567 and general and administrative expenses of $691,760; and
  • Total assets for the quarter ended October 31, 2021 decreased by 13% to $19,079,056 from $21,921,195 for the period ended July 31, 2021, which was mainly attributable to a decreased in cash and cash equivalents.

Management Commentary

“We are pleased with Ketamine One’s financial results for the first quarter of the 2022 fiscal year, as revenue during the three-month period ending October 31st exceeded that for all of the 2021 fiscal year. It’s a great way to start the fiscal year and I am grateful for the keen efforts of our employees across all of our subsidiaries and to our sage advisors as well,” said Adam Deffett, Interim CEO of Ketamine One. “Ketamine One continues to execute on its plan to become a leader in mental health across North America. Our businesses, including KGK Science and IRP Health, are growing in multiple ways and we are optimistic about the financial performance of the Company for the remainder of the fiscal year as we nurture our existing industry partnerships, cultivate new ones and explore other opportunities as they arise,” added Mr. Deffett.

Subsequent Highlighted Events (all amounts expressed in Canadian Dollars unless otherwise noted)

  • Virtual Mental Healthcare Platform in Partnership With iHealthOX: On November 4, announced that it had entered into a telehealth and virtual health partnership to increase accessibility and service offerings to its patients (the “Telehealth Strategy”). In order to better address the needs of patients as well as incorporate the Telehealth Strategy across its portfolio of mental health clinics, contract research capabilities and its focus on digital therapeutics, the Company had also announced the launch of a new patient-facing website at www.ketamine.one/patients/home.
  • Intention to Submit Draft Registration Statement for Proposed U.S. Initial Public Offering: On November 9, announced that it intended to confidentially submit a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to a potential initial public offering (“IPO”) of its common shares in the United States. The IPO is expected to be for up to USD 20 Million of Ketamine One’s common shares and is currently expected by Company management to occur in the first half of 2022. The number of common shares to be offered, the use of proceeds, and the price range for the proposed IPO have not yet been determined.
  • IRP Health Opened Two New Veteran-Focused Clinics: On November 16, announced that its wholly owned subsidiary, IRP Health Ltd. (“IRP” or the “Subsidiary”), opened its Comox Valley and Ottawa clinics (the “Two Clinics”). As previously announced, the Two Clinics are veteran-focused facilities and multidisciplinary in nature. To date, IRP has successfully performed over 10,000 unique treatments for past or present personnel of the Canadian Armed Forces and the Royal Canadian Mounted Police (“RCMP”), as well as first responders including firefighters, law enforcement officers, paramedics and emergency medical technicians.
  • KGK Science Helps Client Receive New Dietary Ingredient Status from U.S. FDA: On December 2, announced that its wholly owned contract research organization, KGK Science Inc., successfully assisted its client, Hofseth Biocare ASA (HBC.OL) (“HBC”), to receive New Dietary Ingredient status from the United States Food and Drug Administration for its patented CalGo® and OmeGo® branded products. HBC is a leading manufacturer and marketer of unique and innovative marine-derived calcium, protein, collagen, and lipid nutritional supplements.
  • Partners with Cognetivity Neurosciences in Collaborative Clinical Study on Depression and PTSD: Also on December 2, announced that it entered into a collaborative partnership with Cognetivity Neurosciences Ltd. (CSE: CGN; OTCQB: CGNSF; FWB: 1UB) (“Cognetivity”) to study and develop assessments for depression and post-traumatic stress disorder (“PTSD”). In the initial stage of the partnership, Cognetivity and Ketamine One will partner on two separate clinical studies, one for depression and the second for PTSD. Protocols for both studies have received Institutional Review Board approval and patient recruitment is expected to occur in early 2022. Ketamine One’s wholly owned subsidiary, KGK Science Inc., will lead the study, while Cognetivity will lead the analysis.
  • Adds Seattle Location To US Clinical Network: On December 8, announced that it had been engaged by Dr. Tami Meraglia to establish a ketamine infusion clinic in Seattle, Washington. The new clinic will operate as Seattle Ketamine Infusions (“SKI” or the “Clinic”) and be located at 311 West Republican Street. Dr. Meraglia is focused on the areas of personalized intravenous treatments and is also a national best-selling author and frequent media guest regarding total health and wellness topics. Ketamine One will provide training, protocol development, and ongoing support for the Clinic, with the first patient treatments expected at SKI in early 2022.
  • Termination of NY Ketamine acquisition: On December 13, the Company announced that it and NY Ketamine Medical Practice, PLLC (“NY Ketamine”) had mutually agreed to terminate the letter of intent previously announced on April 5, 2021 pursuant to which the Company was working to acquire NY Ketamine. Ketamine One remains active in evaluating the acquisition of clinic assets in several US states and is focused on growing its network of existing clinics across North America.
  • Departure of CMO: On December 13, the Company announced that its Chief Medical Officer, Dr. Mark Kimmins, has departed the organization.
  • Appointment of New CFO: On December 14, the Company announced that Joe Ramelli was appointed as Ketamine One’s new Chief Financial Officer (“CFO”) effective December 14, 2021, subject to the final acceptance of the NEO Exchange. Ketamine One’s former CFO, Peter Nguyen, amicably agreed to depart the Company and also resigned from the Company’s Board of Directors effective December 13, 2021.

Outlook (excerpt from Ketamine One’s Management Discussion & Analysis For the Period Ended October 31, 2021 and 2020)

Ketamine One is dedicated to becoming a leader in clinical offerings of ketamine-enhanced treatments across North America. We have acquired 15 clinics across North America, with letters of intent signed for an additional clinic. We are building the critical infrastructure needed to provide breakthrough and life-changing mental wellness treatments through existing clinics, experienced professionals and advanced technology.

Ketamine One will be utilizing first-of-its-kind wearable technologies to track key vitals before, during, and after psychedelic-assisted therapies. Our technology aims to empower patients in their wellness journey and provide clinicians with data to improve outcomes. Building objective data around the patient experience by measuring physical signals and responses will allow us to refine and adjust our processes, while providing great opportunities to advance psychedelic therapy research.

KGK Science, a wholly owned Ketamine One subsidiary, has helped hundreds of companies with custom designed clinical trials and claim substantiation strategies over the past 23 years. Equipped with state-of-the-art technologies, novel research techniques, and a seasoned team of industry experts, KGK Science is a leader in premium clinical research. The company has extensive experience in pharmaceuticals, cannabis, natural health products, and more recently psychedelics.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly-owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

“Adam Deffett“
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Posted on

Ketamine One Announces Lifting Of Management Cease Trade Order

Ketamine One Announces Lifting Of Management Cease Trade Order

Vancouver, British Columbia, December 15, 2021 / Globe Newswire / – KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its management cease trade order granted by the British Columbia Securities Commission on November 1, 2021, was lifted effective immediately following the filing on SEDAR on December 13, 2021 of the Company’s audited annual financial statements and accompanying management’s discussion and analysis for the fiscal year ended July 31, 2021.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE 

“Adam Deffett“

Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations

Tel: 1-844-PHONE-K1 (1-844-746-6351)

Email: IR@ketamine.one 

Web: www.ketamine.one 

Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

INTERESTED IN WORKING WITH KETAMINE ONE?

If you’re interested in being a financial partner, clinic partner, or community advocate, we’d love to talk. partners@ketamine.one